CN102048747B - Tulathromycin composition used for treating or preventing pet bacterial diseases and preparation method thereof - Google Patents
Tulathromycin composition used for treating or preventing pet bacterial diseases and preparation method thereof Download PDFInfo
- Publication number
- CN102048747B CN102048747B CN 201010571719 CN201010571719A CN102048747B CN 102048747 B CN102048747 B CN 102048747B CN 201010571719 CN201010571719 CN 201010571719 CN 201010571719 A CN201010571719 A CN 201010571719A CN 102048747 B CN102048747 B CN 102048747B
- Authority
- CN
- China
- Prior art keywords
- pharmaceutically acceptable
- thailand
- formula
- chemical compound
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses an application of a tulathromycin composite in treating or preventing pet bacterial diseases, and also discloses a tulathromycin composite used for treating or preventing pet bacterial diseases and a preparation method thereof. The composite disclosed by the invention has the characteristics of less dosage and good curative effect, and is used for preparing medicament widely used clinically.
Description
Technical field
The present invention relates to a kind ofly be used to treat or prevent the Thailand of house pet bacterial disease to draw the mycin composition and method of making the same, belong to the animal drugs field.
Background technology
Raising day by day along with living standards of the people; Increasing people begins to keep a pet; Because the people contacts with the close of house pet, Amphixenosis's propagation also is on the rise, because the entrained former bacterium of Amphixenosis of house pet does not obtain enough concerns; Antibioticly be used to resist a pathogen favourable weapon beyond doubt, but incident drug-resistance of bacteria problem is also more and more serious.According to investigations, the antibiotic problem of house pet veterinary clinic treatment ubiquity abuse human, this has just caused many intravital appearance of animal with chemical sproof Amphixenosis pathogen, thereby causes serious public health problem probably.
Mycin (Tulathromycin) draws in Thailand to be a kind of listing recently and to be the Macrolide semisynthetic antibiotics of animal specific.China Ministry of Agriculture allows Thailand to draw mycin in animal produces, to use in 2008 No. 957 bulletin first, has that antibacterial, bactericidal action, consumption are few, numerous advantages such as single administration, low-residual and animal specific.In China; The existing use of Macrocyclolactone lactone kind medicine is tylosin and tilmicosin comparatively widely, though these two kinds of medicines have all been obtained good effect aborning, along with the prolongation of service time; Drug resistance has in various degree appearred in a lot of areas of China; Cause consumption constantly to increase, but therapeutic effect progressively reducing, and Thailand draw the mycin drug effect all to be better than the widely used Macrocyclolactone lactone kind medicines in market such as tylosin and tilmicosin.Thailand draws mycin not have carcinogenic, teratogenesis and genetoxic, most ofly after the administration excretes with original shape Excreta form, and degrades through effects such as deoxidation, oxidation, hydrolysis, can not produce big influence to environment.Thailand draws mycin oral, and acute very low with subacute toxicity, the fatal dose of dog and Mus is respectively greater than 1000 mg/kg body weight and 2000 mg/kg body weight.During 1000 mg/kg body weight, the breathing rate of dog and Mus, heart rate, body temperature, blood pressure etc. all with normally are as good as.The HAS of Mus is 300 mg/kg body weight; During intravenous injection, it is 10 mg/kg body weight that the maximum of dog and Mus does not have lethal dose.Aspect specific toxicity, tertogenicity test of rat and rat reproduction test confirm no teratogenesis or fetal toxicity.Thailand draws the mycin preparation that injection type is only arranged at present, has the inconvenient problem of administration during large-scale farming, and the cost of injection causes culturing income and reduces than higher.
Summary of the invention
In view of this; Main purpose of the present invention is to provide a kind of Thailand that is used to prevent or treats the house pet bacterial disease to draw mould promotor composition; It is characterized in that; This Thailand draws mould promotor composition to comprise the chemical compound of formula I or chemical compound or its pharmaceutically acceptable salt of its pharmaceutically acceptable salt and formula II, and the structure of its Chinese style I and formula II is following:
Preferably; It is 1-30% that the chemical compound of mould promotor composition Chinese style I or chemical compound or the ratio of its pharmaceutically acceptable salt in compositions of its pharmaceutically acceptable salt and formula II are drawn by Thailand of the present invention, and surplus is that pharmaceutically acceptable preparing carriers becomes liquid preparation and solid preparation.
Preferably, house pet bacterial disease of the present invention comprises that bacterial diarrhea, tonsillitis, infectious colitis, urinary tract infection, otitis media and labyrinthitis, external otitis, conjunctivitis, prostatitis, young cat diarrhoeal diseases, dog pyoderma, enteritis sexually transmitted disease (STD), cat actinomycosis, cat nocardiasis, rich the winning for Salmonella disease, leptospiral infection, the cat plague, Brucella canis disease, cat bartonellosis, dog of cat infect for Salmonella.
Preferably, the consumption of mycin composition medicine draws in Thailand of the present invention, and single dose is 1-30mg/kg.
Preferably, Thailand of the present invention to draw the dosage form of mould promotor composition be liquid preparation and solid preparation.
Preferably, Thailand of the present invention to draw the liquid preparation of mould promotor composition be injection, oral liquid, drop; Solid preparation is tablet, capsule.
Preferably; Thailand of the present invention draws the mycin composite injection to comprise: chemical compound or its pharmaceutically acceptable salt of the chemical compound of formula I or its pharmaceutically acceptable salt and formula II are 1-20%W/V; The 0-5%W/V cosolvent; The 20-50%V/V organic solvent, antioxidant 0.1-0.5%W/V, water for injection is to full dose.
Preferably; Thailand of the present invention draws the mycin oral liquid to comprise: chemical compound or its pharmaceutically acceptable salt of the chemical compound of formula I or its pharmaceutically acceptable salt and formula II are 1-30%W/V; The 0-5%W/V cosolvent, 20-50%V/V organic solvent, the sweeting agent of 10-30%W/V; The 0.05-0.3%W/V antiseptic, purified water is to full dose.
Preferably; Thailand of the present invention draws the mycin drop to comprise: chemical compound or its pharmaceutically acceptable salt of the chemical compound of formula I or its pharmaceutically acceptable salt and formula II are 10-30%W/V; The 0-5%W/V cosolvent; The 20%-50%V/V organic solvent, antioxidant 0.1-0.5%W/V, purified water is to full dose.
Preferably, mould promotor composition draws in Thailand of the present invention, and the method for preparing of liquid preparation comprises:
1) get cosolvent, add water stir make dissolve solution a;
2) in solution a, add Thailand and draw mycin, with acid or adjusting PH with base 6.0-8.0, in 60～80 ℃ of insulation 20min-6h, stir in the time of insulation, insulated and stirred finishes postcooling to room temperature and gets solution b;
3) in solution b, add organic solvent, transfer pH5.3-5.6 with acid.
Preferably, the acid that Thailand of the present invention draws step b in the method for preparing of mould promotor composition liquid preparation to regulate pH comprises hydrochloric acid, sulphuric acid, phosphoric acid, acetic acid, and alkali comprises triethylamine, pyridine, sodium hydroxide, sodium carbonate, sodium bicarbonate.
More preferably, the cosolvent that adopts of liquid preparation of the present invention comprise in citric acid, tartaric acid, malic acid, acetic acid, glutamic acid, tryptophan, phosphoric acid, the hydrochloric acid any one or multiple.
More preferably, the organic solvent of the employing of liquid preparation of the present invention be can with the organic solvent of water mixing, comprise ethanol, propylene glycol, glycerol, Polyethylene Glycol or alpha-pyrrolidone.
More preferably, antioxidant of the present invention comprises thioglycerol, sodium pyrosulfite, sodium sulfite.
More preferably, antiseptic of the present invention comprises sodium benzoate, potassium sorbate, benzoic acid or sorbic acid.
More preferably, sweeting agent of the present invention is sucrose, stevioside.
Preferably, Thailand of the present invention draws the mycin tablet to comprise: chemical compound or its pharmaceutically acceptable salt of the chemical compound of formula I or its pharmaceutically acceptable salt and formula II are 1-30%W/W, and 0-5%W/W cosolvent and pharmaceutically acceptable carrier are to full dose; Mix homogeneously; Granulate, drying adds magnesium stearate 0.1-0.5%W/W; Tabletting is prepared into tablet, the 0.5g/ sheet; Dried granule incapsulated be prepared into capsule, the 0.5g/ grain.
More preferably, the Thailand of the present invention cosolvent that draws the mycin solid preparation to adopt comprise in tartaric acid, citric acid, lauryl sulfate, gluconic acid, malic acid, glutamic acid, the tryptophan any one or multiple.
More preferably, the Thailand of the present invention pharmaceutically acceptable carrier that draws the mycin solid preparation to adopt is the mixture of dextrin and sucrose, glucose or lactose any one or two kinds of mixture compositions.
More preferably, Thailand of the present invention draws the mycin solid preparation to adopt the amount ratio 5%-30%W/W of dextrin.Technique effect
The invention provides and can be used to treat or prevent the Thailand that contains of house pet bacterial disease to draw mould promotor composition, have easy to use, consumption is little, good effect, the little characteristics of side effect.
At first; Thailand of the present invention draws mycin preparation of pharmaceutical compositions method simple, can be solid dosage forms or liquid dosage form, can realize injection, oral liquid or drop and tablet or capsule etc. particularly; Therefore in house pet disease treatment or prevention real work, more convenient to use.Secondly; The present invention compared with treatment of common house pet bacterial disease or prevention in the antibiotic that uses or the therapeutic effect of medicine, find that Thailand of the present invention draws the therapeutic effect of mycin pharmaceutical composition more remarkable, the course of treatment is shorter; It is also faster that house pet recovers; And what is more important, Thailand of the present invention draws the mycin pharmaceutical composition to solve the problem of house pet bacterial drug resistance, the infecting both domestic animals and human disease of having avoided occurring popular.At last, Thailand of the present invention draws the side effect of mycin pharmaceutical composition less, more safe and reliable, more can meet the needs in drug safety relevant regulations and market.。
The specific embodiment
The Thailand of embodiment of the invention preparation draws in the mycin composition medicine; The chemical compound of the chemical compound of formula I or the ratio of its pharmaceutically acceptable salt and formula II or the ratio of its pharmaceutically acceptable salt; Be merely the preferred usage ratio that mould promotor composition draws in Thailand for preparing of using embodiment of the invention method for preparing; Mould promotor composition draws in the Thailand that the chemical compound of the chemical compound of the formula I of the arbitrary proportion that any other method for preparing or purification process obtain or the ratio of its pharmaceutically acceptable salt and formula II or its pharmaceutically acceptable salt are formed, and its content of effective does not change.
Tested the clinical trial of different drug compositions in the embodiment of the invention to the house pet bacterial disease; Test is found to draw mould promotor composition with Thailand, though that its consumption is compared with similar antibiotic is less, healing time is shorter; And cure rate is higher, can treat or prevent the house pet bacterial disease effectively.
Tested Thailand among the embodiment of the invention 1-4 and drawn the therapeutic effect of the medicine of mould promotor composition, proved the safe bacteriostasis of mycin of drawing common house pet bacterial disease pathogen to dog, cat bacterial diarrhea, tonsillitis, infectious colitis, otitis media.Draw among mycin broad-spectrum bactericidal action and the embodiment 1-4 bacteriostasis to common house pet bacterial disease pathogen based on Thailand, Thailand draws the medicine of mould promotor composition also to can be used for house pet bacterial disease such as urinary tract infection, labyrinthitis, external otitis, conjunctivitis, prostatitis, young cat diarrhoeal diseases, dog pyoderma, enteritis sexually transmitted disease (STD), cat actinomycosis, cat nocardiasis, rich the winning for Salmonella disease, leptospiral infection, the cat plague, Brucella canis disease, cat bartonellosis, dog of cat infected for Salmonella.
Embodiment 5-11; Having prepared Thailand draws the Thailand of mycin different dosage form different content to draw the mycin composition medicine; The medicine of mould promotor composition draws in the common formulations of other this area house pet medicine and the Thailand of other content; Draw mycin because of its effective ingredient is Thailand, all can treat or prevent the house pet bacterial disease effectively.
For making the present invention be more prone to understand,, further set forth the present invention below in conjunction with specific embodiment.Should be understood that these embodiment only to be used to the present invention is described and be not used in and limit scope of the present invention, NM concrete experimental technique in the following example carries out according to the normal experiment method usually.
The application of mould promotor composition in the injection pharmaceutical composition of preparation treatment house pet bacterial disease drawn by embodiment 15%W/V Thailand
The preparation of mycin injection is drawn by 1.5%W/V Thailand
Mycin (chemical compound of the chemical compound of mass percent 90% formula I and mass percent 10% formula II) 5%W/V draws in Thailand
Citric acid 1%W/V
Propylene glycol 30%V/V
Thioglycerol 0.5%W/V
1000ml adds to the full amount of water for injection
Method for preparing: get citric acid 10g, add injection water 500ml, stir and make dissolving, Jia Taila mycin 50g; Dilute hydrochloric acid is transferred pH7.0, and 70 ℃ of insulation 30min stir in the time of insulation, and stirring is placed to room temperature after finishing; Add propylene glycol 300ml, hydrochloric acid is transferred pH5.5, adds thioglycerol 5g, adds the injection water to 1000ml; Mixing, 0.22 μ m filter membrane filters, fill, sterilization promptly gets.
2.5%W/V Thailand draw the mycin injection to dog, cat by salmonellal diarrheal therapeutic effect
The test house pet: test 23 dogs and 26 cats all are to be diagnosed as bacterial diarrhea, these samples are cases of pet clinic's collection in 2009 to 2010.
Diagnostic criteria: found in the feces of animal or in the blood of septicemia animal that Salmonella then can make a definite diagnosis.
Clinical symptoms: acute diarrhea (also containing blood and mucus in the sometimes diarrhoea thing), vomiting, fervescence, anorexia, spirit are depressed, stomachache etc.
Test is divided into groups and Therapeutic Method: drug group (12 dog, 13 cats) gives 5% Thailand and draws the mycin injection, 0.2mg/kg, every day 1 time, successive administration 2 days; Matched group (11 dog, 13 cats) intramuscular injection 10% tylosin injection 0.2ml/kg, every day 1 time, successive administration 2 days, every day 1 time.
Observing time and index: observed 3 days continuously after the last administration, diarrhoea situation, vomiting, body temperature, appetite, the mental status, cure rate does not continue to observe to the 5th day if recover fully after 3 days.
Clinical efficacy: according to observation index, write down diarrhoea situation, vomiting situation, body temperature, appetite, the mental status, the cure rate of dog, cat every day, the result sees table 1, wherein cure rate=healing bar (only) number/test bar (only) number * 100%.
Each item index relatively after table 1 drug group and the treatment of control group
| Group | Drug group | Matched group |
| The diarrhoea situation | Do not have | 4 cat diarrhoea |
| Vomiting | Do not have | Do not have |
| Body temperature | Normally | Normally |
| Appetite | Normally | Article 3, dog and 2 cat anorexia |
[0052]
| The mental status | 2 dog spirit are depressed | 4 cat spirit are depressed |
| Cure rate after 3 days after the first administration | 80.0% | 64.0% |
| Cure rate after 5 days after the first administration | 92.0% | 72.50% |
Can find out from table 1; Drug group (mycin injection group is drawn by 5% Thailand) cure rate is than matched group (tylosin injection group) height; And the healing time of drug group is shorter; The recovery extent of drug group is good than the matched group recovery, explains that adopting the present composition to be used to treat dog cat diarrhoea has good therapeutic effect.
3.5%W/V Thailand draws the mycin injection to dog, the tonsillitic therapeutic effect of cat
The test house pet: test 22 dogs and 20 cats all are to be diagnosed as tonsillitis, these samples are cases of pet clinic's collection in 2009 to 2010.
Clinical symptoms: congested, the heating of antiadoncus, spirit is depressed, dysphagia, loss of appetite, shake the head etc.
Test is divided into groups and Therapeutic Method: drug group (11 dog, 10 cats) gives 5% Thailand and draws the mycin injection, 2mg/kg, every day 1 time, successive administration 5 days; Matched group (11 dog, 10 cats) intramuscular injection 30% lincomycin hydrochloride injection 10mg, every day 2 times, successive administration 5 days, every day 1 time.
Observing time and index: the last administration is observed tonsil red and swollen situation, body temperature, is swallowed situation, the mental status, cure rate after 24 hours.
Clinical efficacy: according to observation index, write down every day dog, cat peach body red and swollen situation, body temperature, swallow situation, the mental status, cure rate, the result sees table 2.
Each item index relatively after table 2 drug group and the treatment of control group
| Group | Drug group | Matched group |
| The red and swollen situation of tonsil | Do not have | 2 cats and 1 dog tonsil are swollen slightly |
| Body temperature | Do not have | Do not have |
| Swallow situation | Normally | Article 3, dog and 2 cat anorexia |
[0062]
| The mental status | 3 dog spirit are depressed | 3 cat spirit are depressed |
| Cure rate after 5 days after the first administration | 71.4% | 61.9% |
| Cure rate after 7 days after the first administration | 85.7% | 71.4% |
Can find out from table 2; Drug group (mycin injection group is drawn by 5% Thailand) cure rate is than matched group (lincomycin hydrochloride injection group) height; And the healing time of drug group is shorter; The recovery extent of drug group is good than the matched group recovery, explains that adopting the present composition to be used to treat dog cat tonsillitis has good therapeutic effect.
Mycin oral liquor and application thereof are drawn by embodiment 210%W/V Thailand
The mycin oral liquor draws in 1.10%W/V Thailand
Mycin phosphate (phosphate of the chemical compound of the phosphate of the chemical compound of mass percent 95% formula I and mass percent 5% formula II) 10%W/V draws in Thailand
Propylene glycol 50%V/V
Sucrose 20%W/V
Sodium benzoate 0.1%W/V
Add purified water to full dose
Method for preparing: get purified water 300ml, Jia Taila mycin phosphate 100g, 10% sodium hydrate aqueous solution is transferred pH8.0,80 ℃ of insulation 20min; Stir in the time of insulation, stirring is placed to room temperature after finishing, and adds propylene glycol 500ml, and hydrochloric acid is transferred pH5.5; 200g makes dissolving with sucrose, adds sodium benzoate 1g, adds purified water to 1000ml; Mixing, fill, sterilization promptly gets.
2. the safe therapeutic effect of mycin oral liquid that draw to canine infectious colitis
The experiment house pet: testing 23 dogs all is to be diagnosed as infectious colitis, and these samples are cases of pet clinic's collection in 2009 to 2010.
Diagnostic criteria: can make diagnosis through colonoscope and colonic mucosa biopsy.
Clinical symptoms: animal shows as feces feels like jelly, and has blood, symptom such as have fervescence, mucus excrement when being in a bad way, lose weight.
Test is divided into groups and Therapeutic Method: drug group (12 dog) gives 10% Thailand and draws the mycin oral liquid, consumption 1ml, every day 1 time, successive administration 7 days; Matched group (11 dog) gives sulfasalazine 20mg/kg, every day 2 times, successive administration 7 days.
Observing time and index: the last administration was write down the situation of having blood in stool, the cure rate of dog every day after 24 hours.
Clinical efficacy: according to observation index, the situation of having blood in stool, the cure rate of statistics dog, the result sees table 3.
Each item index relatively after table 3 drug group and the treatment of control group
| Group | Drug group | Matched group |
| The situation of having blood in stool | Do not have | Still have 4 dogs to have blood in stool |
| Cure rate | 83.3％ | ?63.6％ |
Can find out from table 3; Drug group (mycin oral liquid group is drawn by 10% Thailand) cure rate is than matched group (sulfasalazine group) height; Drug group the situation of having blood in stool do not occur after treatment; And matched group still has 3 to have blood in stool, and explains that adopting the present composition to be used to treat canine infectious colitis has good therapeutic effect.
3. Thailand draws the mycin oral liquid to dog, the tonsillitic therapeutic effect of cat
The experiment house pet: test 25 dogs and 19 cats all are to be diagnosed as tonsillitis, these samples are cases of pet clinic's collection in 2009 to 2010.
Clinical symptoms: congested, the heating of antiadoncus, spirit is depressed, dysphagia, loss of appetite, shake the head etc.
Test is divided into groups and Therapeutic Method: drug group (14 dog, 9 cats) gives 10% Thailand and draws the mycin oral liquid, consumption 1ml, every day 1 time, successive administration 2 days; Matched group (11 dog, 10 cats) intramuscular injection 10% tylosin injection 0.2ml/kg, every day 2 times, successive administration 2 days.
Observing time and index: the last administration is observed tonsil red and swollen situation, body temperature, is swallowed situation, the mental status, cure rate after 24 hours.
Clinical efficacy: according to observation index, write down every day dog, cat peach body red and swollen situation, body temperature, swallow situation, the mental status, cure rate, the result sees table 4.
Each item index relatively after table 4 drug group and the treatment of control group
| Group | Drug group | Matched group |
| The red and swollen situation of tonsil | Do not have | 2 cats and 1 dog tonsil are swollen slightly |
| Body temperature | Do not have | Do not have |
| Swallow situation | Normally | Article 2, dog and 2 cat anorexia |
| The mental status | 5 dog spirit are depressed | 3 cat spirit are depressed |
| Cure rate after 5 days after the first administration | ?73.9％ | 68.4％ |
| Cure rate after 7 days after the first administration | ?78.2％ | 73.8％ |
Can find out from table 4; Drug group (mycin oral liquid group is drawn by 10% Thailand) cure rate is than matched group (tylosin injection group) height; And the healing time of drug group is shorter; The recovery extent of drug group is good than the matched group recovery, explains that adopting the present composition to be used to treat dog cat tonsillitis has good therapeutic effect.
Capsular method for preparing of mycin and application thereof are drawn by embodiment 3 Thailands
1. the capsular method for preparing of mycin is drawn by Thailand
Thailand draws mycin meter Thailand to draw mycin tartrate (tartrate of the chemical compound of the tartrate of the chemical compound of 90% mass percent formula I and 10% mass percent formula II) 10%W/W
Dextrin 20%W/W
With sucrose to full dose
Method for preparing: get Thailand and draw mycin tartrate 100g, dextrin 200g, sucrose 700g, mix homogeneously is prepared into granule, and drying incapsulates, and promptly gets the 0.5g/ grain.
2. the safe therapeutic effect of mould cellulose capsule that draw to the cat bacterial diarrhea
The test house pet: test 24 dogs and 16 cats all are to be diagnosed as bacterial diarrhea, these samples are cases of pet clinic's collection in 2009 to 2010.
Clinical symptoms: acute diarrhea (also containing blood and mucus in the sometimes diarrhoea thing), vomiting, fervescence, anorexia, spirit are depressed, stomachache etc.
Test is divided into groups and Therapeutic Method: drug group (12 dog, 8 cats) gives Thailand and draws mould cellulose capsule, consumption be 1/inferior, 1 time/day, successive administration 2 days; Matched group (11 dog, 13 cats) intramuscular injection 10% tylosin injection 0.2ml/kg, every day 1 time, successive administration 2 days, every day 1 time.
Observing time and index: with reference to embodiment 1.
Clinical efficacy: with reference to embodiment 1.
Each item index relatively after table 5 drug group and the treatment of control group
| Group | Drug group | Matched group |
| The diarrhoea situation | Do not have | Article 2, dog is suffered from diarrhoea |
| Vomiting | Do not have | Do not have |
| Body temperature | Normally | 1 cat is undesired |
| Appetite | Normally | Article 2, dog and 1 cat anorexia |
| The mental status | Article 3, dog spirit is depressed | 3 cat spirit are depressed |
| Cure rate after 3 days after the first administration | ?70.0％ | 61.8％ |
| Cure rate after 5 days after the first administration | ?85.0％ | 76.1％ |
Can find out from table 5; Drug group (the mycin Capsules group is drawn by 5% Thailand) cure rate is than matched group (10% tylosin injection group) height; And the healing time of drug group is shorter; The recovery extent of drug group is good than the matched group recovery, explains that adopting the present composition to be used to treat dog cat diarrhoea has good therapeutic effect.
The method for preparing and the application thereof of mycin drop drawn by embodiment 415%W/V Thailand
1. safe method for preparing of drawing the mycin drop
Mycin (chemical compound of the chemical compound of 80% mass percent formula I and 20% mass percent formula II) 15%W/V draws in Thailand
Tartaric acid 3%W/V
Polyethylene Glycol 50%V/V
Add purified water to full dose
Method for preparing: get tartaric acid 30g, add purified water 300ml, stir and make dissolving, Jia Taila mycin 150g; Acetic acid is transferred pH5.0, and 70 ℃ of insulation 6h stir in the time of insulation, and stirring is placed to after finishing; Add Polyethylene Glycol 500ml, hydrochloric acid is transferred pH5.5, adds purified water to 1000ml; Mixing, fill, sterilization promptly gets.
2. the safe therapeutic effect of mycin drop that draw to the dog otitis media
The test house pet: testing 24 dog cats all is to be diagnosed as otitis media, and these samples are cases of pet clinic's collection in 2009 to 2010.
Diagnostic criteria: the middle ear content identifies antibacterial through drug sensitive test.
Clinical symptoms: ear etc. is shaken the head, turn-takes (changeing to Ipsilateral), wiped on the ground to infected animal.
Test is divided into groups and Therapeutic Method: drug group (12 dog) gives 15% Thailand and draws the mycin drop, and 3/inferior, 3 times/day, successive administration 2 days; Matched group (12 dog) gives 10% tylosin injection 0.2ml/kg, successive administration 2 days, every day 1 time.
Observing time and index: with reference to embodiment 1.
Clinical efficacy: according to observation index, the situation of turn-taking of record dog (changeing) behind the last administration 24h to Ipsilateral, wipe the ear situation on the ground, whether the middle ear content has antibacterial, the result sees table 1.
Each item index relatively after table 5 drug group and the treatment of control group
Can find out from table 5, drug group (mycin drop group is drawn by 15% Thailand), the recovery extent of drug group is good than the matched group recovery, explains that adopting the present composition to be used to treat the dog otitis media has good therapeutic effect.
The method for preparing that the mycin sheet draws in embodiment 5 Thailands
Mycin phosphate (chemical compound of 100% formula I) 20%W/W draws in Thailand
Malic acid 5%W/W
Dextrin 20%W/W
Magnesium stearate 0.3%W/W
With sucrose to full dose
Method for preparing: get Thailand and draw mycin phosphate 200g, dextrin 200g, malic acid 50g, sucrose 550g, mix homogeneously is prepared into granule, and drying adds magnesium stearate 3g, and tabletting promptly gets, the 0.5g/ sheet.
The preparation that the mycin injection draws in embodiment 610%W/V Thailand
Mycin (chemical compound of the chemical compound of 90% mass percent formula I and 10% mass percent formula II) 10%W/V draws in Thailand
Propylene glycol 50%V/V
Sodium pyrosulfite 0.2%W/V
1000ml adds to the full amount of water for injection
Method for preparing: get Thailand and draw mycin 100g, add injection water 400ml, add acetic acid and transfer pH8.0,60 ℃ of insulation 1h; Stir in the time of insulation, stirring is placed to room temperature after finishing, and adds propylene glycol 500ml, and hydrochloric acid is transferred pH5.3; Add sodium pyrosulfite 2g, add the injection water to 1000ml, mixing; 0.22 μ m filter membrane filters, fill, and sterilization promptly gets.
The mycin oral liquor draws in embodiment 71%W/V Thailand
Mycin phosphate (phosphate of the chemical compound of the phosphate of the chemical compound of 95% mass percent formula I and 5% mass percent formula II) 1%W/V draws in Thailand
Ethanol 30%V/V
Sucrose 10%W/V
Potassium sorbate 0.1%W/V
Add purified water to full dose
Method for preparing: get purified water 300ml, Jia Taila mycin phosphate 10g adds 10% sodium hydrate aqueous solution and transfers pH7.0,60 ℃ of insulation 3h; Stir in the time of insulation, stirring is placed to room temperature after finishing, and adds ethanol 300ml, and hydrochloric acid is transferred pH5.6; 100g makes dissolving with sucrose, adds potassium sorbate 1g, adds purified water to 1000ml; Mixing, fill, sterilization promptly gets.
The capsular method for preparing of mycin is drawn by embodiment 8 Thailands
Mycin phosphate (phosphate of the chemical compound of the phosphate of the chemical compound of 10% mass percent formula I and 90% mass percent formula II) 10%W/W draws in Thailand
Dextrin 20%W/W
With sucrose to full dose
Method for preparing: get Thailand and draw mycin tartrate 100g, dextrin 200g, sucrose 700g, mix homogeneously is prepared into granule, and drying incapsulates, and promptly gets the 0.5g/ grain.
Embodiment 9 draws the method for preparing of mycin sheet with Thailand
Mycin tartrate (chemical compound of the chemical compound of 90% mass percent formula I and 10% mass percent formula II) 30%W/V draws in Thailand
Dextrin 15%W/W
Magnesium stearate 0.1%W/W
With sucrose to full dose
Method for preparing: get Thailand and draw mycin tartrate 300g, dextrin 150g, sucrose 550g, mix homogeneously is prepared into granule, and drying adds magnesium stearate 1g, and tabletting promptly gets, the 0.5g/ sheet.The mycin oral liquor draws in embodiment 1015%W/V Thailand
Mycin (chemical compound of the chemical compound of 90% mass percent formula I and 10% mass percent formula II) 15%W/V draws in Thailand
Citric acid 3%W/V
Propylene glycol 50%V/V
Sucrose 20%W/V
Sodium benzoate 0.1%W/V
Add purified water to full dose
Method for preparing: get citric acid 30g, add purified water 300ml, stir and make dissolving, Jia Taila mycin 150g; Add phosphoric acid and transfer pH7.0,70 ℃ of insulation 30min stir in the time of insulation, and stirring is placed to room temperature after finishing; Add propylene glycol 500ml, hydrochloric acid is transferred pH5.5, and 200g makes dissolving with sucrose, adds sodium benzoate 1g; Add purified water to 1000ml, mixing, fill, sterilization promptly gets.
Mycin drop method for preparing is drawn by embodiment 1120%W/V Thailand
Mycin (chemical compound of the chemical compound of 90% mass percent formula I and 10% mass percent formula II) 15%W/V draws in Thailand
Tryptophan 4%W/V
Glycerol 50%V/V
Add purified water to full dose
Method for preparing: get tryptophan 40g, add purified water 300ml, stir and make dissolving, Jia Taila mycin 150g; Add acetic acid and transfer pH7.5,70 ℃ of insulation 30min stir in the time of insulation, and stirring is placed to room temperature after finishing; Glycerol adding 500ml, hydrochloric acid is transferred pH5.5, adds purified water to 1000ml; Mixing, fill, sterilization promptly gets.
The above is merely preferred embodiment of the present invention, and is in order to restriction the present invention, not all within spirit of the present invention and principle, any modification of being done, is equal to replacement, improvement etc., all should be included within protection scope of the present invention.
Claims (11)
1. the application of mould promotor composition aspect prevention or treatment house pet bacterial disease drawn by a Thailand; Described Thailand draws mould promotor composition to comprise the chemical compound of formula I or chemical compound or its pharmaceutically acceptable salt of its pharmaceutically acceptable salt and/or formula II, and the structure of its Chinese style I and formula II is following:
Wherein, It is liquid preparation and solid preparation that the dosage form of mould promotor composition is drawn by said Thailand; Contain cosolvent 0-5%W/V in said liquid preparation and the solid preparation; The chemical compound of the chemical compound of described formula I or its pharmaceutically acceptable salt and/or formula II or the ratio of its pharmaceutically acceptable salt in compositions are 1-30%W/W; Surplus is pharmaceutically acceptable carrier, it is characterized in that, described house pet bacterial disease comprises that rich the winning for Salmonella disease, leptospiral infection, the cat plague, Brucella canis disease, cat bartonellosis, dog of bacterial diarrhea, tonsillitis, infectious colitis, urinary tract infection, otitis media, labyrinthitis, external otitis, conjunctivitis, prostatitis, young cat diarrhoeal diseases, dog pyoderma, enteritis sexually transmitted disease (STD), cat actinomycosis, cat nocardiasis, cat infect for Salmonella.
2. the application of mould promotor composition is drawn by Thailand according to claim 1, it is characterized in that, the single dose of described compositions is 1-30mg/kg.
3. the application of mould promotor composition is drawn by Thailand according to claim 2, it is characterized in that, described liquid preparation is injection, oral liquid or drop; Described solid preparation is tablet or capsule.
4. the application of mould promotor composition is drawn by Thailand according to claim 3, it is characterized in that, described injection comprises:
The chemical compound of the chemical compound of formula I or its pharmaceutically acceptable salt and/or formula II or its pharmaceutically acceptable salt are 1-20%W/V, the 0-5%W/V cosolvent, and the 20-50%V/V organic solvent, antioxidant 0.1-0.5%W/V, water for injection is to full dose.
5. the application of compositions according to claim 3 is characterized in that, described oral liquid comprises:
The chemical compound of the chemical compound of formula I or its pharmaceutically acceptable salt and formula II or its pharmaceutically acceptable salt are 1-30%W/V; The 0-5%W/V cosolvent; The 20-50%V/V organic solvent, the sweeting agent of 10-30%W/V, antioxidant 0.1-0.5%W/V; The 0.05-0.3%W/V antiseptic, purified water is to full dose.
6. the application of compositions according to claim 5 is characterized in that, described sweeting agent is sucrose, stevioside.
7. the application of compositions according to claim 3; It is characterized in that; Described drop comprises: chemical compound or its pharmaceutically acceptable salt of the chemical compound of formula I or its pharmaceutically acceptable salt and formula II are 10-30%W/V, 0-5%W/V cosolvent, 20%-50%V/V organic solvent; Antioxidant 0.1-0.5%W/V, purified water is to full dose.
8. according to any application that mould promotor composition draws in described Thailand of claim 4～7, it is characterized in that described Thailand draws mycin preparation of compositions method to comprise:
1) get cosolvent, add water stir make dissolve solution a;
2) in solution a, add the chemical compound of formula I or chemical compound or its pharmaceutically acceptable salt of its pharmaceutically acceptable salt or formula II; With acid or adjusting PH with base 6.0-8.0; In 60～80 ℃ of insulation 20min-6h, stir in the time of insulation, insulated and stirred finishes postcooling to room temperature and gets solution b;
3) in solution b, add organic solvent, transfer pH5.3-5.6 with acid.
9. according to the application of any described compositions of claim 4～7, it is characterized in that, described cosolvent comprise in citric acid, tartaric acid, malic acid, acetic acid, glutamic acid, tryptophan, phosphoric acid, the hydrochloric acid any one or multiple; The organic solvent of described organic solvent for dissolving each other with water comprises ethanol, propylene glycol, glycerol, Polyethylene Glycol or alpha-pyrrolidone; Described antioxidant comprises thioglycerol, sodium pyrosulfite, sodium sulfite; Described antiseptic comprises sodium benzoate, potassium sorbate, benzoic acid or sorbic acid.
10. the application of compositions according to claim 3 is characterized in that, described tablet comprises: chemical compound or its pharmaceutically acceptable salt of the chemical compound of formula I or its pharmaceutically acceptable salt and formula II are 1-30%W/W; 0-5%W/W cosolvent and pharmaceutically acceptable carrier are to full dose, and mix homogeneously is granulated; Dry; The dried granule of gained adds magnesium stearate 0.1-0.5%W/W, and tabletting is prepared into tablet, the 0.5g/ sheet; Described capsule comprises: above-mentioned dried granule is incapsulated be prepared into capsule, the 0.5g/ grain.
11. the application of compositions according to claim 10 is characterized in that, described cosolvent comprise in tartaric acid, citric acid, lauryl sulfate, gluconic acid, malic acid, glutamic acid, the tryptophan any one or multiple; Described pharmaceutically acceptable carrier is dextrin and sucrose, glucose or lactose any one or two kinds of mixture that mixture is formed; Said dextrin is ratio 5%-30%W/W in granule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010571719 CN102048747B (en) | 2010-12-01 | 2010-12-01 | Tulathromycin composition used for treating or preventing pet bacterial diseases and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010571719 CN102048747B (en) | 2010-12-01 | 2010-12-01 | Tulathromycin composition used for treating or preventing pet bacterial diseases and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102048747A CN102048747A (en) | 2011-05-11 |
| CN102048747B true CN102048747B (en) | 2012-12-12 |
Family
ID=43953764
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201010571719 Active CN102048747B (en) | 2010-12-01 | 2010-12-01 | Tulathromycin composition used for treating or preventing pet bacterial diseases and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102048747B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101647808A (en) * | 2008-08-14 | 2010-02-17 | 洛阳惠中兽药有限公司 | Pharmaceutical composition for treating respiratory diseases of livestock and poultry, preparation method thereof and application thereof |
-
2010
- 2010-12-01 CN CN 201010571719 patent/CN102048747B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101647808A (en) * | 2008-08-14 | 2010-02-17 | 洛阳惠中兽药有限公司 | Pharmaceutical composition for treating respiratory diseases of livestock and poultry, preparation method thereof and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102048747A (en) | 2011-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019204496B2 (en) | Anti-diarrhea formulation which avoids antimicrobial resistance | |
| CN103690940B (en) | Compound dimetridazole premix for preventing and treating poultry enterovirus syndrome | |
| CN101991640A (en) | Preparation method of mahonia fortune-containing Chinese medicinal composition and application thereof | |
| CN104906121B (en) | Pharmaceutical composition containing tylonolide | |
| CN102048747B (en) | Tulathromycin composition used for treating or preventing pet bacterial diseases and preparation method thereof | |
| CN103285396A (en) | Medicine composition for eradicating helicobacter pylori, as well as preparation method and application | |
| ES2290195T3 (en) | USE OF CARBON HYDRATES TO ELIMINATE INTESTINAL INFECTIONS IN ANIMALS. | |
| CN104922140A (en) | Tildipirosin composition and applications thereof in treating or preventing poultry respiratory tract diseases | |
| CN102614294B (en) | Compound amoxicillin suspension injection and preparation method thereof | |
| CN101987105A (en) | Compound preparation for treating diseases caused by poultry sensitive bacteria and preparation method thereof | |
| CN103908670B (en) | A kind of compound treating poultry coli-infection disease | |
| CN101953871B (en) | Antibacterial medicament for animals and preparation method and application thereof | |
| CN101301280A (en) | Sustained release tablet products used as helminthic of livestock | |
| CN101757069A (en) | Oral medical liquid for treating chicken mixed infection as well as preparation method and application thereof | |
| CN103211818A (en) | Pharmaceutical composition for treating or preventing bacterial and mycoplasma diseases of livestock and use thereof | |
| CN101987117A (en) | Traditional Chinese medicine composition for treating bacterial diseases in poultry and livestock and preparation method thereof | |
| CN1845738B (en) | Composition for veterinary and medical use | |
| CN101984976A (en) | Compositions for veterinary and medical applications | |
| CN104208011B (en) | Azithromycin syrup agent and preparation method thereof | |
| CN107714838A (en) | A kind of Chinese medicine composition for preventing and treating diarrhea of weaned piglets and its application | |
| ES2907081T3 (en) | Composition for the treatment of constipation | |
| CN103142744B (en) | Effervescent granules for preventing and treating piglet diarrhea | |
| CN103784948A (en) | Effervescent suppository for treating mammal vaginitis | |
| CN101850105A (en) | Cefuroxime sodium composite medicine | |
| CN114515274A (en) | Acidified amoxicillin soluble powder and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |